Xconomy | Boston - Business + Technology in the Exponential Economy

British Biotech Antisoma Sees Buyout of Xanthus as Beginning of U.S. Commercial Hub in Cambridge, MA
Alnylam Adds Another RNA Approach, Vertex Tackles Hardest Hep C Cases, Zafgen Places Big Bet on Fat Shrinkers, & More Life Sciences News
A Diagnostics Non-Profit Takes the 100K Prize, Greenfuel Gets a $13.9M Bump for Algae Bioreactors, Beth Israel Teams With Google, and More Life Sciences News
GlaxoSmithKline Scoops Up Sirtris
Facet Rejects Biogen Takeover Bid

Xanthus Sold for $52M

British drug company Antisoma reported today that it has picked up Cambridge, MA-based Xanthus Pharmaceuticals for about $52 million in shares. Xanthus focuses on therapies for cancer and autoimmune diseases and has five drugs in clinical development. One of them is an oral cancer drug that is already marketed outside the U.S. by Bayer-Schering Pharma.

Erik Mellgren is a Swedish journalist who worked for Xconomy Boston in 2008 as part of the Stanford Innovation Journalism Fellowship program. His real job is with Ny Teknik, a leading technology and innovation magazine in Sweden, but he loved seeing the Red Sox at Fenway.

Comments | Reprints | Share: